These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 29675946)
21. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758 [TBL] [Abstract][Full Text] [Related]
22. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103 [TBL] [Abstract][Full Text] [Related]
23. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease. Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812 [TBL] [Abstract][Full Text] [Related]
24. TAFRO Syndrome. Igawa T; Sato Y Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612 [TBL] [Abstract][Full Text] [Related]
25. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy. Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942 [TBL] [Abstract][Full Text] [Related]
26. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome. Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479 [TBL] [Abstract][Full Text] [Related]
27. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease]. Okamoto S Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845 [TBL] [Abstract][Full Text] [Related]
28. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741 [TBL] [Abstract][Full Text] [Related]
29. Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease. Harada T; Kikushige Y; Miyamoto T; Uno K; Niiro H; Kawakami A; Koga T; Akashi K; Yoshizaki K Nat Commun; 2023 Oct; 14(1):6959. PubMed ID: 37907518 [TBL] [Abstract][Full Text] [Related]